Inhibition of advanced glycation end product formation by cymene - A common food constituent

Journal of Functional Foods

Volumn 6, Issue 1, 2014, Pages 107-115

  Joglekar, Madhav M ^a   Panaskar, Shrimant N ^a   Arvindekar, Akalpita U ^a  

^a SHIVAJI UNIVERSITY   (India)

Author keywords

AGE fluorescence; Cymene; Glycation inhibition; Protein conformation

Indexed keywords

EID: 84895067160     PISSN: 17564646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jff.2013.09.024     Document Type: Article

References (49)

1. Aebi H. Catalase: Methods of enzymatic analysis 1974, Academic Press, New York, pp. 667-673.
2. Ansari N.A., Ali R. Physicochemical analysis of poly-l-lysine: An insight into the changes induced in lysine residues of proteins on modification with glucose. IUBMB Life 2011, 63:26-29.
3. Arai K., Maguchi S., Fujii S., Ishibashi H., Oikawa K., Taniguchi N. Glycation and inactivation of human Cu-Zn-superoxide dismutase. The Journal of Biological Chemistry 1987, 262:16969-16972.
4. Bettaieb I., Bourgou S., Sriti J., Msaada K., Limam F., Marzouk B. Essential oils and fatty acids composition of Tunisian and Indian cumin (Cuminum cyminum L.) seeds: A comparative study. Journal of the Science of Food and Agriculture 2011, 91:2100-2107.
5. Bhattacharya J., GhoshMoulick R., Choudhuri U., Chakrabarty P., Bhattacharya P.K., Lahiri P., Chakraborti V., Dasgupta A.K. Unfolding of hemoglobin variants - Insights from urea gradient gel electrophoresis photon correlation spectroscopy and zeta potential measurements. Analytica Chimica Acta 2004, 522:207-214.
6. Bolton W.K., Cattran D.C., Williams M.E. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. American Journal of Nephrology 2004, 24:32-40.
7. Bron A.J., Vrensen G.F., Koretz J., Maraini G., Harding J.J. The ageing lens. Ophthalmologica 2000, 214:86-104.
8. Bucala R., Cerami A. Advanced glycosylation: Chemistry, biology, and implications for diabetes and aging. Advances in Pharmacology 1992, 23:1-34.
9. Charonis A.S., Tsilibary E.C. Structural and functional changes of laminin and type IV collagen after nonenzymatic glycosylation. Diabetes 1992, 41:49-54.
10. 1c and fructosamine. Diabetes Care 2003, 26:163-167.
11. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal Medicine 1993, 329:977. The Diabetes Control and Complications Trial Research Group.
12. Derham B.K., Harding J.J. Alpha-crystallin as a molecular chaperone. Progress in Retinal and Eye Research 1999, 18:463-509.
13. Doumas B.T., Watson W.A., Biggs H.G. Albumin standards and the measurement of serum albumin with bromcresol green. Clinica Chimica Acta 1971, 31:87-96.
14. EAFUS: A Food Additive Database U. S. Food and Drug Administration Center for Food Safety and Applied Nutrition, 1998.
15. Edwards C.A., O'Brien W.D. Modified assay for determination of hydroxyproline in a tissue hydrolyzate. Clinica Chimica Acta 1980, 104:161-167.
16. Ellman G.L. Tissue sulfhydryl groups. Archives of Biochemistry and Biophysics 1959, 82:70-77.
17. Farrukh A.S., Sharkey E., Creighton D. Maillard reactions in lens proteins: Methylglyoxal-mediated modifications in the rat lens. Experimental Eye Research 2000, 70:369-380.
18. Ferard G. Quantities and units for electrophoresis in the clinical laboratory. Clinical chemistry division, commission on quantities and units in clinical chemistry. Pure and Applied Chemistry 1994, 66:891-896. Printed in Great Britain.
19. Forbes J.M., Soulis T., Thallas V., Panagiotopoulos S., Long D.M., Vasan S., Wagle D., Jerums G., Cooper M.E. Renopretective effects of a novel inhibitor of advanced glycation. Diabetologia 2001, 44:108-114.
20. Goldstein D.E., Parker K.M., England J.D., England J.E., Wiedmeyer H.M., Rawlings S.S. Clinical application of glycosylated hemoglobin measurements. Diabetes 1982, 31:70-78.
21. Guerois R., Lopez de la Paz M. Protein design methods and applications 2006, Humana press, New Jersey, pp. 3-26.
22. Jean-Luc W., Schmidt A.M. Protein glycation: A firm link to endothelial cell dysfunction. Circulation Research 2004, 95:233-238.
23. Joglekar M.M., Panaskar S.N., Chougale A.D., Kulkarni M.J., Arvindekar A.U. A novel mechanism for antiglycative action of limonene through stabilization of protein conformation. Molecular BioSystems 2013, 9:2463-2472.
24. Johnson R.N., Metcalf P.A., Baker J.R. Fructosamine: A new approach to the estimation of serum glycosylprotein. An index of diabetic control. Clinica Chimica Acta 1983, 127:87-95.
25. Kumar M.S., Reddy P.Y., Kumar P.A., Surolia I., Reddy G.B. Effect of dicarbonyl-induced browning on alpha-crystallin chaperone-like activity: Physiological significance and caveats of in vitro aggregation assays. Biochemical Journal 2004, 379:273-282.
26. Liggins J., Furth A.J. Mixed dimers formed by crosslinking of native and glycated proteins in the absence of free sugar. Biochemical and Biophysical Research Communications 1996, 219:186-190.
27. Lo T.W., Selwood T., Thornalley P.J. The reaction of methylglyoxal with aminoguanidine under physiological conditions and prevention of methylglyoxal binding to plasma proteins. Biochemical Pharmacology 1994, 48:1865-1870.
28. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. The Journal of Biological Chemistry 1951, 193:265-275.
29. Marklund S., Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. European Journal of Biochemistry 1974, 47:469-474.
30. Miller E.J., Rhodes R.K. Preparation and characterization of different types of collagen. Methods in Enzymology 1982, 82:33-64.
31. Miyata T., Kurokawa K., Ypersele De Strihou C.V. Advanced glycation and lipoxidation end products: Role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. Journal of American Society for Nephrology 2000, 11:1744-1752.
32. 2Microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway implications for the pathogenesis of dialysis-related amyloidosis. Journal of Clinical Investigation 1996, 98:1088-1094.
33. Monnier V.M., Vishwanath V., Frank K.E., Elmets C.A., Dauchot P., Kohn R.R. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. New England Journal of Medicine 1986, 314:403-408.
34. Mott J.D., Khalifah R.G., Nagase H., Shield C.F., Hudson J.K., Hudson B.G. Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney International 1997, 52:1302-1312.
35. Nakamura A., Goto S. Analysis of protein carbonyls with 2, 4-dinitrophenyl hydrazine and its antibodies by immunoblot in two-dimensional gel electrophoresis. Journal of Biochemistry 1996, 119:768-774.
36. Nakhjavani M., Farzami B., Golmohammadi T., Jaafarzadeh A. Measurement of advanced glycosylation end-products in diabetic patients by isoelectric focusing and fluorescence, to monitor disease progression. Journal of Diabetes and Metabolic Disorders 2003, 2:36-40.
37. Nangaku M. Mechanisms of tubulointerstitial injury in the kidney: Final common pathways to end-stage renal failure. Internal Medicine 2004, 43:9-17.
38. Panaskar S.N., Joglekar M.M., Taklikar S.S., Haldavnekar V.S., Arvindekar A.U. Aegle marmelos Correa leaf extract prevents secondary complications in streptozotocin-induced diabetic rats and demonstration of limonene as a potent antiglycating agent. Journal of Pharmacy and Pharmacology 2013, 65:884-894.
39. Paul R.G., Bailey A.J. The effect of advanced glycation end-product formation upon cell-matrix interactions. The International Journal of Biochemistry & Cell Biology 1999, 31:653-660.
40. Rahbar S., Natarajan R., Kumar K., Yerneni K.K., Scott S., Gonzales N., Nadler N.J. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clinica Chimica Acta 2000, 301:65-77.
41. Schmidt M.A., Stern D.M. RAGE: A new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends in Endocrinology and Metabolism 2000, 11:368-375.
42. Sell D.R., Monnier V.M. Isolation, purification and partial characterization of novel fluorophores from aging human insoluble collagen-rich tissue. Connective Tissue Research 1989, 19:77-92.
43. Sensi M., Pricci Grazla De Rossi M., Morano S., Mario U. d-lysine effectively decreases the non-enzymic glycation of proteins in vitro. Clinical Chemistry 1989, 35:384-387.
44. Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications Trial. Kidney International 1995, 47:1703-1720. The Diabetes Control and Complications Trial.
45. Van Boekel M.A.M., Van Den Bergh P.J.P.C., Hoenders H.J. Glycation of human serum albumin: Inhibition by diclofenac. Biochemica et Biophysica Acta 1992, 1120:201-204.
46. Wells-Knecht K.J., Brinkmann E., Wells-Knecht M.C., Litchfield J.E., Ahmed M.U., Reddy S., Zyzak D.V., Thorpe S.R., Baynes J.W. New biomarkers of maillard reaction damage to proteins. Nephrology Dialysis Transplantation 1996, 11:41-47.
47. William M.E. Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease. Current Diabetes Report 2004, 4:441-446.
48. Woessner J.E. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Archives of Biochemistry and Biophysics 1968, 93:440-447.
49. Wolffenbuttel B.H., Boulanger C.M., Crijns F.R. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proceedings of National Academy of Sciences United States of America 1998, 95:4630-4634.